{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+B+Cell&page=22",
    "query": {
      "condition": "Leukemia, Lymphocytic, B Cell",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1890,
    "total_pages": 189,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+B+Cell&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Lymphocytic%2C+B+Cell&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T12:26:16.620Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02199184",
      "title": "Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Burkitt Lymphoma",
        "Atypical Burkitt/Burkitt-Like Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Burkitt Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Burkitt Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 14,
      "start_date": "2015-01-14",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02199184"
    },
    {
      "nct_id": "NCT00088868",
      "title": "17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "alvespimycin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088868"
    },
    {
      "nct_id": "NCT01039376",
      "title": "Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukaemia, Lymphocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 480,
      "start_date": "2010-05-06",
      "completion_date": "2018-06-26",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 43,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 37 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01039376"
    },
    {
      "nct_id": "NCT05535855",
      "title": "UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoid Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CD19 Directed CAR T Cell",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2024-01-24",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05535855"
    },
    {
      "nct_id": "NCT04318678",
      "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML/MDS",
        "B-ALL",
        "T-ALL",
        "BPDCN"
      ],
      "interventions": [
        {
          "name": "CD123-CAR T",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 108,
      "start_date": "2020-07-29",
      "completion_date": "2030-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 2,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04318678"
    },
    {
      "nct_id": "NCT00006390",
      "title": "Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-07-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 14,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006390"
    },
    {
      "nct_id": "NCT01416974",
      "title": "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "modified T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2011-08-22",
      "completion_date": "2019-01-07",
      "has_results": false,
      "last_update_posted_date": "2019-01-11",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416974"
    },
    {
      "nct_id": "NCT01024010",
      "title": "Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Stage 0 Chronic Lymphocytic Leukemia",
        "Stage I Chronic Lymphocytic Leukemia",
        "Stage I Small Lymphocytic Lymphoma",
        "Stage II Chronic Lymphocytic Leukemia",
        "Stage II Small Lymphocytic Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2010-03",
      "completion_date": "2017-09-28",
      "has_results": true,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024010"
    },
    {
      "nct_id": "NCT01589302",
      "title": "PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prolymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory/Relapsed Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Correlative laboratory samples",
          "type": "OTHER"
        },
        {
          "name": "quality of life assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kami Maddocks, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2012-05-21",
      "completion_date": "2026-10-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01589302"
    },
    {
      "nct_id": "NCT04809467",
      "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "parsaclisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-16",
      "completion_date": "2024-10-22",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-15T12:26:16.620Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04809467"
    }
  ]
}